Telix Pharmaceuticals (NASDAQ:TLX) Upgraded by Royal Bank Of Canada to "Moderate Buy" Rating

Key Points

• Royal Bank of Canada upgraded Telix Pharmaceuticals from “Hold” to “Moderate Buy,” while the broader analyst consensus remains “Buy” with an average price target of $20.40.
• Telix shares traded down 10.2%, opening at $11.31; the stock remains below its 52-week high of $13.11 but above its 52-week low of $6.28.
• Telix and ITM plan to combine their businesses, a move intended to strengthen isotope supplies, expand international reach and support future radiopharmaceutical product launches and revenue growth.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) was upgraded by Royal Bank Of Canada from a "hold" rating to a "moderate buy" rating in a note issued to investors on Monday, Zacks reports.

TLX has been the subject of several other reports. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, August 21st. Wedbush reiterated an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Monday, September 14th. Citigroup reissued a "buy" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, Telix Pharmaceuticals currently has an average rating of "Buy" and an average price target of $20.40.

Telix Pharmaceuticals Trading Down 10.2%

Shares of TLX stock opened at $11.31 on Monday. The stock has a fifty day moving average of $11.30 and a 200 day moving average of $10.38. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $13.11. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its holdings in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. XY Capital Ltd bought a new position in Telix Pharmaceuticals during the 1st quarter valued at approximately $120,000. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at approximately $1,731,000. Private Advisor Group LLC raised its stake in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after buying an additional 128,070 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock worth $2,775,000 after acquiring an additional 39,400 shares in the last quarter.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix and ITM plan to combine their complementary businesses to create a larger radiopharmaceutical company, strengthening Telix’s access to radioisotope production, development capabilities and international markets. Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
• Positive Sentiment: The deal is intended to improve the security and scale of Telix’s isotope supply, potentially supporting future product launches, manufacturing growth and long-term revenue expansion. Telix and ITM merge to create a radiopharmaceutical powerhouse
• Positive Sentiment: Management’s merger presentation and call emphasized the strategic rationale for building a scaled radiopharmaceutical leader, which could create synergies and broaden Telix’s competitive position if integration is successful. Telix Pharmaceuticals M&A Call Transcript

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.